



## Product Pipeline

With the recent FDA approval of KETARx™ for surgical pain management (anesthesia and sedation for surgical and diagnostic procedures), PharmaTher is executing a progressive plan to establish category leadership in the U.S. while advancing additional indications via the efficient 505(b)(2) pathway—particularly in rare disorders, where orphan-drug incentives and real-world evidence (RWE) can accelerate timelines.

# KETARx™ Strategic Plan

With KETARx™ now FDA Approved, we are advancing an ambitious 'capital-efficient' commercial & regulatory initiative to unlock new indications and opportunities

Commercialization in growing surgical and diagnostic procedural uses

505(b)(2) "literature-based" NDA strategy for rare and ultra-rare disorders



PHARMATHER  
OTCQB: PHRRF | CSE: PHRM


## KETARx™ Ketamine Portfolio

Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Approval
Pain and Surgery Management					
Complex Regional Pain Syndrome		Published & Exclusive Access to RWE & RCTs Data to Support NDA via 505(b)(2)			
Undisclosed Rare disorder		Published & Exclusive Access to RWE & RCTs Data to Support NDA via 505(b)(2)			
Parkinson's Disease	Adaptive Phase 3 ready. Seeking Pharm Partner			Patent No. 12,128,012, expiring May 14, 2041	
ALS	Phase 1/2 ready. Grant funding.			Patent No. 11,426,366, expiring May 5, 2036	
		Current	12-18 Months		

RWE: Real-world Evidence  
RCTs - Randomized Clinical Trials

PHARMATHER  
OTCQB: PHRRF | CSE: PHRM

# KETARx™ Growth Pathway



PHARMATHER  
OTCQB: PHRRF | CSE: PHRM

## KETARx™ Opportunities

### Seeking Pharma Partnerships

#### Adaptive Phase 3 study



Parkinson's Disease  
(Levodopa-induced dyskinesia)

#### Microneedle Hydrogel Patch



Novel delivery technologies administering Ketamine for hospital, clinic and home use



#### Sub-Q On-Body Pump

PHARMATHER  
OTCQB: PHRRF | CSE: PHRM

## Connect With Us



PharmaTher Holdings Ltd.  
82 Richmond Street East  
Toronto, Ontario Canada  
M5C 1P1



© COPYRIGHT 2025. PharmaTher Holdings Ltd. ALL RIGHTS RESERVED.